160 related articles for article (PubMed ID: 19069358)
1. Clinical experience with posaconazole in patients with invasive mucormycosis: a case series.
González-Ramos MM; Bertrán-Pasarell J; Guiot H; Soto R; Santana J; Amador R; Conde A
P R Health Sci J; 2008 Dec; 27(4):328-32. PubMed ID: 19069358
[TBL] [Abstract][Full Text] [Related]
2. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.
Mezhir JJ; Mullane KM; Zarling J; Satoskar R; Pai RK; Roggin KK
Surg Infect (Larchmt); 2009 Oct; 10(5):447-51. PubMed ID: 19485785
[TBL] [Abstract][Full Text] [Related]
3. Mucormycosis treated with posaconazole: review of 96 case reports.
Vehreschild JJ; Birtel A; Vehreschild MJ; Liss B; Farowski F; Kochanek M; Sieniawski M; Steinbach A; Wahlers K; Fätkenheuer G; Cornely OA
Crit Rev Microbiol; 2013 Aug; 39(3):310-24. PubMed ID: 22917084
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.
Rickerts V; Atta J; Herrmann S; Jacobi V; Lambrecht E; Bialek R; Just-Nübling G
Mycoses; 2006; 49 Suppl 1():27-30. PubMed ID: 16961579
[TBL] [Abstract][Full Text] [Related]
5. [Mucormycosis: retrospective evaluation of 12 cases].
Arda B; Erdem A; Sipahi OR; Işıkgöz Taşbakan M; Pullukçu H; Taşbakan MS; Ceylan N; Metin DY; Midilli R; Yamazhan T; Ulusoy S
Mikrobiyol Bul; 2011 Jul; 45(3):504-11. PubMed ID: 21935783
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole for the treatment of mucormycosis.
Enoch DA; Aliyu SH; Sule O; Lewis SJ; Karas JA
Int J Antimicrob Agents; 2011 Dec; 38(6):465-73. PubMed ID: 21782392
[TBL] [Abstract][Full Text] [Related]
7. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.
Tobón AM; Arango M; Fernández D; Restrepo A
Clin Infect Dis; 2003 Jun; 36(11):1488-91. PubMed ID: 12766845
[TBL] [Abstract][Full Text] [Related]
8. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation.
Mousset S; Bug G; Heinz WJ; Tintelnot K; Rickerts V
Transpl Infect Dis; 2010 Jun; 12(3):261-4. PubMed ID: 19954497
[TBL] [Abstract][Full Text] [Related]
10. Use of posaconazole in the treatment of infective rhinocerebral mucormycosis.
Kulendra K; Habibi M; Butler C; Clarke P; Howard D
J Laryngol Otol; 2010 Dec; 124(12):1314-7. PubMed ID: 20388246
[TBL] [Abstract][Full Text] [Related]
11. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Nagappan V; Deresinski S
Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis.
Scheckenbach K; Cornely O; Hoffmann TK; Engers R; Bier H; Chaker A; Greve J; Schipper J; Wagenmann M
Auris Nasus Larynx; 2010 Jun; 37(3):322-8. PubMed ID: 19857939
[TBL] [Abstract][Full Text] [Related]
13. Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae.
Kok J; Gilroy N; Halliday C; Lee OC; Novakovic D; Kevin P; Chen S
J Infect; 2007 Sep; 55(3):e33-6. PubMed ID: 17624436
[TBL] [Abstract][Full Text] [Related]
14. Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl.
Tarani L; Costantino F; Notheis G; Wintergerst U; Venditti M; Di Biasi C; Friederici D; Pasquino AM
Pediatr Diabetes; 2009 Jun; 10(4):289-93. PubMed ID: 18828793
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy.
Almannai M; Imran H; Estrada B; Siddiqui AH
Pediatr Hematol Oncol; 2013 Apr; 30(3):184-6. PubMed ID: 23444832
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole for treatment of refractory invasive fungal disease.
Notheis G; Tarani L; Costantino F; Jansson A; Rosenecker J; Friederici D; Belohradsky BH; Reinhardt D; Seger R; Schweinitz DV; Wintergerst U
Mycoses; 2006; 49 Suppl 1():37-41. PubMed ID: 16961581
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
18. [Mucormycosis: therapeutic news].
Pilmis B; Lanternier F; Lortholary O
Med Sci (Paris); 2013 Mar; 29 Spec No 1():25-30. PubMed ID: 23510522
[TBL] [Abstract][Full Text] [Related]
19. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B.
Sedlacek M; Cotter JG; Suriawinata AA; Kaneko TM; Zuckerman RA; Parsonnet J; Block CA
Am J Kidney Dis; 2008 Feb; 51(2):302-6. PubMed ID: 18215708
[TBL] [Abstract][Full Text] [Related]
20. Experimental murine model of disseminated infection by Saksenaea vasiformis: successful treatment with posaconazole.
Salas V; Pastor FJ; Calvo E; Sutton D; García-Hermoso D; Mayayo E; Dromer F; Fothergill A; Alvarez E; Guarro J
Med Mycol; 2012 Oct; 50(7):710-5. PubMed ID: 22458251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
